Nevertheless, despite all the promising data proved in preclinical models, the role of TIM-3 hasn't been evaluated in clinical trials yet, maybe due to the insufficient evidence of TIM-3′s role in clinical cancer patients. The gene discussed is HAVCR2; the disease is cancer.